[HTML][HTML] Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for …
H Yoshioka, M Shimokawa, T Seto, S Morita… - Annals of …, 2019 - Elsevier
Background Primary analysis of the phase III study WJTOG 3405 demonstrated superiority of
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
progression-free survival (PFS) for gefitinib (G) in patients treated with the epidermal growth …
Final overall survival results of WJTOG 3405, a randomized phase 3 trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for …
H Yoshioka, T Mitsudomi, S Morita, Y Yatabe, S Negoro… - 2014 - ascopubs.org
8117 Background: WJTOG3405 has proven that chemotherapy-naïve patients with
postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFR mutation have …
postoperative recurrent or stage IIIB/IV NSCLC harboring activating EGFR mutation have …
Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for …
T Mitsudomi, S Morita, Y Yatabe, S Negoro, I Okamoto… - 2012 - ascopubs.org
7521 Background: WJTOG3405 met its primary endpoint of progression free survival
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …
(PFS)(9.2 months (mo.) for G vs. 6.3 mo. for CD, hazard ratio (HR) 0.489, 95% confidence …
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation …
H Tada, T Mitsudomi, T Misumi, K Sugio… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To investigate the efficacy of gefitinib as an adjuvant therapy for non–small-cell
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
lung cancer patients with EGFR mutation. PATIENTS AND METHODS IMPACT …
Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin (CBDCA) plus paclitaxel (TXL) as the first-line treatment for advanced non …
A Inoue, K Kobayashi, M Maemondo… - Journal of Clinical …, 2011 - ascopubs.org
7519 Background: NEJ002 have demonstrated a significant superiority of gefitinib on
progression-free survival compared with CBDCA plus PTX (CP) as the first-line treatment for …
progression-free survival compared with CBDCA plus PTX (CP) as the first-line treatment for …
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with …
A Nakamura, A Inoue, S Morita, Y Hosomi, T Kato… - 2018 - ascopubs.org
9005 Background: Although EGFR-TKI alone has been a standard first-line treatment for pts
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
with advanced NSCLC with EGFR mutations, our phase II study (NEJ005) showed …
Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
E Miyauchi, S Morita, A Nakamura, Y Hosomi… - Journal of clinical …, 2022 - ascopubs.org
Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned …
report, typically based on the primary end point, may be published when key planned …
[HTML][HTML] Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin–paclitaxel for chemo-naïve non-small cell lung cancer …
A Inoue, K Kobayashi, M Maemondo, S Sugawara… - Annals of oncology, 2013 - Elsevier
Background NEJ002 study, comparing gefitinib with carboplatin (CBDCA) and paclitaxel
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
(PTX; Taxol) as the first-line treatment for advanced non-small cell lung cancer (NSCLC) …
Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations
S Morita, I Okamoto, K Kobayashi, K Yamazaki… - Clinical Cancer …, 2009 - AACR
Purpose: Somatic mutations of the epidermal growth factor receptor (EGFR) gene are
associated with an increased response to gefitinib in patients with non–small cell lung …
associated with an increased response to gefitinib in patients with non–small cell lung …
[HTML][HTML] Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression …
Aim: Most patients (pts) with EGFR mutation-positive NSCLC respond to 1st-line EGFR
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …
tyrosine kinase inhibitors, but later acquire resistance. The Phase III, double-blind IRESSA …